ImmunityBio, Inc. financial data

Symbol
IBRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3530 John Hopkins Court, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
NantKwest, Inc. (to 3/8/2021), Conkwest, Inc. (to 7/13/2015), ZelleRx Corp (to 10/9/2009)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 358 % +1252%
Debt-to-equity -174 % -4.73%
Return On Equity 100 % +8.83%
Return On Assets -134 % +4.36%
Operating Margin -115K % -82.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 697M shares +52.7%
Common Stock, Shares, Outstanding 692M shares +57%
Entity Public Float 316M USD +4.57%
Common Stock, Value, Issued 69K USD +56.8%
Weighted Average Number of Shares Outstanding, Basic 687M shares +57%
Weighted Average Number of Shares Outstanding, Diluted 687M shares +57%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 302K USD -48.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1.05M USD +2454%
Research and Development Expense 204M USD -22%
Operating Income (Loss) -360M USD +3.32%
Nonoperating Income (Expense) -238M USD -134%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -598M USD -26.1%
Income Tax Expense (Benefit) -40K USD -218%
Net Income (Loss) Attributable to Parent -598M USD -26.3%
Earnings Per Share, Basic -0.96 USD/shares +15%
Earnings Per Share, Diluted -0.96 USD/shares +15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 130M USD +199%
Marketable Securities, Current 87.9M USD +3490%
Accounts Receivable, after Allowance for Credit Loss, Current 1.03M USD
Inventory, Net 1.81M USD
Other Assets, Current 480K USD -89.5%
Assets, Current 243M USD +263%
Property, Plant and Equipment, Net 142M USD -6.29%
Operating Lease, Right-of-Use Asset 33.8M USD -20.5%
Intangible Assets, Net (Excluding Goodwill) 16.1M USD -15.4%
Other Assets, Noncurrent 2.66M USD -29.5%
Assets 444M USD +52.6%
Accounts Payable, Current 33.6M USD +241%
Accrued Liabilities, Current 35.3M USD -43.3%
Liabilities, Current 62.1M USD -89.9%
Deferred Income Tax Liabilities, Net 162K USD -4.71%
Operating Lease, Liability, Noncurrent 36.4M USD -18.2%
Other Liabilities, Noncurrent 704K USD +48.8%
Liabilities 1.14B USD +21.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -8K USD +80%
Retained Earnings (Accumulated Deficit) -3.23B USD -22.7%
Stockholders' Equity Attributable to Parent -698M USD -8.76%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -697M USD -8.09%
Liabilities and Equity 444M USD +52.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -107M USD -26.9%
Net Cash Provided by (Used in) Financing Activities 10.2M USD -86.7%
Net Cash Provided by (Used in) Investing Activities -35.6M USD -320%
Common Stock, Shares Authorized 1.35B shares +50%
Common Stock, Shares, Issued 692M shares +57%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -132M USD -719%
Interest Paid, Excluding Capitalized Interest, Operating Activities 23.9M USD +54.1%
Deferred Tax Assets, Valuation Allowance 648M USD +31.9%
Deferred Tax Assets, Gross 683M USD +30.4%
Operating Lease, Liability 42.7M USD -15.6%
Depreciation 16M USD -5.88%
Payments to Acquire Property, Plant, and Equipment 1.26M USD -85%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -598M USD +2.41%
Lessee, Operating Lease, Liability, to be Paid 58.1M USD -16.9%
Property, Plant and Equipment, Gross 234M USD +2.25%
Operating Lease, Liability, Current 6.25M USD +4.43%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.98M USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD -10.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14.8M USD -23.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.22M USD -20.1%
Deferred Tax Assets, Operating Loss Carryforwards 421M USD +16.1%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 35.5M USD +118%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.47M USD +3.12%
Operating Lease, Payments 2.38M USD -25%
Amortization of Intangible Assets 2M USD 0%
Depreciation, Depletion and Amortization 4.56M USD -2.69%
Share-based Payment Arrangement, Expense 45.1M USD +7.65%
Interest Expense 126M USD +17.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%